The DOI matches its Crossref record; 63 of the 65 references it cites were found in a registry or an index.
BCL11A enhancer dissection by Cas9-mediated in situ saturating mutagenesis
Open accessAbstract
Enhancers, critical determinants of cellular identity, are commonly recognized by correlative chromatin marks and gain-of-function potential, although only loss-of-function studies can demonstrate their requirement in the native genomic context. Previously, we identified an erythroid enhancer of human BCL11A, subject to common genetic variation associated with the fetal haemoglobin level, the mouse orthologue of which is necessary for erythroid BCL11A expression. Here we develop pooled clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 guide RNA libraries to perform in situ saturating mutagenesis of the human and mouse enhancers. This approach reveals critical minimal features and discrete vulnerabilities of these enhancers. Despite conserved function of the composite enhancers, their architecture diverges. The crucial human sequences appear to be primate-specific. Through editing of primary human progenitors and mouse transgenesis, we validate the BCL11A erythroid enhancer as a target for fetal haemoglobin reinduction. The detailed enhancer map will inform therapeutic genome editing, and the screening approach described here is generally applicable to functional interrogation of non-coding genomic elements.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The authors flow-sorted the edited cells on the basis of the BCL11A-dependent switch to fetal haemoglobin, sequenced guides enriched in cells that had or hadn’t switched, and on the basis of those enrichments, successfully identified a primate-specific GATA1 motif critical for that enhancer’s function.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Cas9 introduces a targeted double-strand break, which is repaired by homology-directed repair using the donor templates, resulting in the incorporation of a single variant at the endogenous genomic locus (54, 55).”
From Massively parallel functional genomic assays in endocrinology: from promise to delivery (2026) · cites this paper as [54]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The first such screen targeted gRNAs to effectively tile small indels across a known cluster of enhancers of BCL11A195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Canver et al 9 recently showed BCL11A enhancer disruption by CRISPR/Cas9 could induce fetal haemoglobin in both mice and primary human erythroblast cells.”
From What is CRISPR/Cas9? (2016) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The initial CRISPR screens of regulatory elements delivered an individual gRNA per cell195.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
The cited source says what the claim attributes to it.
In the citing paper
“To date, all such screens use Cas9-induced perturbations, including active Cas9 for sequence disruption195, or nuclease dead-Cas9 (dCas9) tethered to an epigenetic repressor105 or activator domain92.”
From Towards a comprehensive catalogue of validated and target-linked human enhancers (2020) · cites this paper as [195]
In the citing paper
“In contrast, nine recently published CRISPR screens of noncoding sequences cumulatively studied regulatory effects on a total of 17 genes (Canver et al., 2015; Diao et al., 2016, 2017; Fulco et al., 2016; Gasperini et al., 2017; Klann et al., 2017; Korkmaz et al., 2016; Rajagopal et al., 2016; Sanjana et al., 2016).”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
In the citing paper
“First, they focus on the regulation of a single gene per experiment, typically entailing the development of a gene-specific assay.”
From A Genome-wide Framework for Mapping Gene Regulation via Cellular Genetic Screens (2019) · cites this paper as Canver et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
Self-citationRNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Self-citationGenome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Self-citationDNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
Self-citationHistone H3K27ac separates active from poised enhancers and predicts developmental state
Creyghton, M. P., Cheng, A. W., Welstead, G. G., Kooistra, T., Carey, B. W., Steine, E. J., Hanna, J., Lodato, M. A., Frampton, G. M., Sharp, P. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016071107 · Cited by 4,302
FIMO: scanning for occurrences of a given motif
Grant, C. E., Bailey, T. L., & Noble, W. S. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr064 · Cited by 4,247
Master Transcription Factors and Mediator Establish Super-Enhancers at Key Cell Identity Genes
Whyte, W. A., Orlando, D. A., Hnisz, D., Abraham, B. J., Lin, C. Y., Kagey, M. H., Rahl, P. B., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.035 · Cited by 4,143
Systematic Localization of Common Disease-Associated Variation in Regulatory DNA
Maurano, M. T., Humbert, R., Rynes, E., Thurman, R. E., Haugen, E., Wang, H., Reynolds, A. P., Sandstrom, R., Qu, H., Brody, J., et al. (2012) · Science · doi:10.1126/science.1222794 · Cited by 3,716
Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity
Ran, F. A., Hsu, P. D., Lin, C.-Y., Gootenberg, J. S., Konermann, S., Trevino, A. E., Scott, D. A., Inoue, A., Matoba, S., Zhang, Y., et al. (2013) · Cell · doi:10.1016/j.cell.2013.08.021 · Cited by 3,299
Self-citation
Cited by
Sorted by citations
Items 501–600 of 883
Current and future gene therapies for hemoglobinopathies
Brendel, C., & Williams, D. A. (2020) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000581 · Cited by 15
Ohno, T., Akase, T., Kono, S., Kurasawa, H., Takashima, T., Kaneko, S., & Aizawa, Y. (2022) · Nature Communications · doi:10.1038/s41467-022-31982-1 · Cited by 14
Effective therapies for sickle cell disease: are we there yet?
Crossley, M., Christakopoulos, G. E., & Weiss, M. J. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.07.003 · Cited by 18
Spisák, S., Tisza, V., Nuzzo, P. V., Seo, J.-H., Pataki, B., Ribli, D., Sztupinszki, Z. M., Bell, C. A., Rohanizadegan, M., Stillman, D. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40616-z · Cited by 14
CRISPR links to long noncoding RNA function in mice: A practical approach
Miano, J. M., Long, X., & Lyu, Q. (2019) · Vascular Pharmacology · doi:10.1016/j.vph.2019.02.004 · Cited by 14
Genome editing to define the function of risk loci and variants in rheumatic disease
Baglaenko, Y., Macfarlane, D., Marson, A., Nigrovic, P. A., & Raychaudhuri, S. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00637-8 · Cited by 12
Genome-wide annotation of gene regulatory elements linked to cell fitnessPreprint
ter Weele, M., Klann, T. S., Barrera, A., Ettyreddy, A. R., Liu, S., Rickels, R. A., Bryois, J., Jiang, S. W., Adkar, S. S., Iglesias, N., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.08.434470 · Cited by 16
Understanding fundamental principles of enhancer biology at a model locus
Kassouf, M. T., Ford, S., Blayney, J., & Higgs, D. R. (2023) · BioEssays · doi:10.1002/bies.202300047 · Cited by 13
Finotti, A., & Gambari, R. (2023) · Frontiers in Genome Editing · doi:10.3389/fgeed.2023.1204536 · Cited by 13
Base Editors-Mediated Gene Therapy in Hematopoietic Stem Cells for Hematologic Diseases
Zhang, C., Xu, J., Wu, Y., Xu, C., & Xu, P. (2024) · Stem Cell Reviews and Reports · doi:10.1007/s12015-024-10715-5 · Cited by 16
Enhancer regulatory networks globally connect non-coding breast cancer loci to cancer genes
Wang, Y., Armendariz, D. A., Wang, L., Zhao, H., Xie, S., & Hon, G. C. (2025) · Genome biology · doi:10.1186/s13059-025-03474-0 · Cited by 13
Zhang, H., Zhou, Q., Chen, H., & Lu, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095002 · Cited by 13
CRISPR/Cas9-mediated gene editing. A promising strategy in hematological disorders
Ugalde, L., Fañanas-Baquero, S., Torres-Ruiz, R., Bustamante, O. Q., & Rı́o, P. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2022.11.014 · Cited by 16
Enhancers are genes that express organizational RNAs
Mattick, J. S. (2023) · Frontiers in RNA Research · doi:10.3389/frnar.2023.1194526 · Cited by 10
Application of CRISPR-Cas system in gene therapy: Pre-clinical progress in animal model
Guan, L., Han, Y., Zhu, S., & Lin, J. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.07.004 · Cited by 13
The advances in CRISPR technology and 3D genome
Wang, W., Zhang, L., Wang, X., & Zeng, Y. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.07.009 · Cited by 13
The Scope for Thalassemia Gene Therapy by Disruption of Aberrant Regulatory Elements
Patsali, P., Mussolino, C., Ladas, P., Floga, A., Kolnagou, A., Christou, S., Sitarou, M., Antoniou, M. N., Cathomen, T., Lederer, C. W., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111959 · Cited by 13
Integrated design, execution, and analysis of arrayed and pooled CRISPR genome editing experimentsPreprint
Canver, M. C., Haeussler, M., Bauer, D. E., Orkin, S. H., Sanjana, N. E., Shalem, O., Yuan, G., Zhang, F., Concordet, J., & Pinello, L. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/125245 · Cited by 13
Self-citationEnhancing CRISPR deletion via pharmacological delay of DNA-PKcsPreprint
Bosch-Guiteras, N., Uroda, T., Guillen-Ramirez, H., Riedo, R., Gazdhar, A., Esposito, R., Pulido-Quetglas, C., Zimmer, Y., Medová, M., & Johnson, R. (2021) · Genome Research · doi:10.1101/gr.265736.120 · Cited by 13
Inhibiting ferroptosis enhances ex vivo expansion of human haematopoietic stem cells
della Volpe, L., Lee, A., Antoszewski, M., Deik, A., Safina, K. R., Gao, T., Guo, C., Ye, T., Lyu, P., Martin-Rufino, J. D., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01814-7 · Cited by 15
Gene therapy and gene editing strategies in inherited blood disorders
Song, X., Liu, J., Chen, T., Zheng, T., Wang, X., & Guo, X. (2024) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2024.07.004 · Cited by 13
Transcriptional Repressor BCL11A in Erythroid Cells
Zheng, G., & Orkin, S. H. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-62731-6_9 · Cited by 13
Self-citationSobral, A. F., Dinis‐Oliveira, R. J., & Barbosa, D. J. (2024) · Forensic Science International Genetics · doi:10.1016/j.fsigen.2024.103163 · Cited by 14
Yang, H. M., Zheng, G., Li, G. Y., Alshaye, A., & Orkin, S. H. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108077 · Cited by 12
Self-citationSahu, S. U., Castro, M., Muldoon, J. J., Asija, K., Wyman, S. K., Krishnappa, N., de Oñate, L., Eyquem, J., Nguyen, D. N., & Wilson, R. C. (2025) · Nature Protocols · doi:10.1038/s41596-025-01154-8 · Cited by 19
Genetic control of erythropoiesis
Tumburu, L., & Thein, S. L. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000333 · Cited by 10
Canver, M. C., Tripathi, P., Bullen, M. J., Olshansky, M., Kumar, Y., Wong, L. H., Turner, S. J., Lessard, S., Pinello, L., Orkin, S. H., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.013772 · Cited by 12
Self-citationHeterogeneity of fetal hemoglobin production in adult red blood cells
Khandros, E., & Blobel, G. A. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000640 · Cited by 12
Ding, J., Frantzeskos, A., & Orozco, G. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00887-4 · Cited by 12
Zhu, M., Huangfu, C., Wan, W., Wang, M., Lv, H., Zhang, X., Wang, F., Zhi, H., Huang, Y., Chen, M., et al. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.1c05315 · Cited by 12
HMGA2 Moderately Increases Fetal Hemoglobin Expression in Human Adult Erythroblasts
de Vasconcellos, J. F., Lee, Y. T., Byrnes, C., Tumburu, L., Rabel, A., & Miller, J. L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166928 · Cited by 12
Cui, M., Lin, C.-Y., & Su, Y. (2017) · Briefings in Functional Genomics · doi:10.1093/bfgp/elx011 · Cited by 12
Discovering functional sequences with RELICS, an analysis method for CRISPR screens
Fiaux, P. C., Chen, H. V., Chen, P. B., Chen, A. R., & McVicker, G. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008194 · Cited by 9
Epigenetics, Enhancer Function and 3D Chromatin Organization in Reprogramming to Pluripotency
Hörnblad, A., & Remeseiro, S. (2022) · Cells · doi:10.3390/cells11091404 · Cited by 14
Rajendiran, V., Devaraju, N., Haddad, M., Ravi, N. S., Panigrahi, L., Paul, J., Gopalakrishnan, C., Wyman, S. K., Ariudainambi, K., Mahalingam, G., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.023 · Cited by 12
Self-citationA single-cell atlas of chromatin accessibility in mouse organogenesis
Sun, K., Liu, X., & Lan, X. (2024) · Nature Cell Biology · doi:10.1038/s41556-024-01435-6 · Cited by 11
The present and future of genome editing in cancer research
Li, X., Wu, R., & Ventura, A. (2016) · Human Genetics · doi:10.1007/s00439-016-1713-3 · Cited by 12
Zhu, X., Xi, C., Ward, A., Takezaki, M., Shi, H., Peterson, K. R., & Pace, B. S. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370220945305 · Cited by 11
The Cas9 Hammer—and Sickle: A Challenge for Genome Editors
Urnov, F. D. (2021) · The CRISPR Journal · doi:10.1089/crispr.2021.29120.fur · Cited by 11
Junker, L. H., Li, Y., Zhu, X., Koti, S., Cerbone, R. E., Hendrick, C. L., Sangerman, J., Perrine, S. P., & Pace, B. S. (2021) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2021.102626 · Cited by 11
Enhancer-Mediated Formation of Nuclear Transcription Initiation Domains
Gibbons, M. D., Fang, Y., Spicola, A. P., Linzer, N., Jones, S. M., Johnson, B. R., Li, L., Xie, M., & Bungert, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169290 · Cited by 12
Ontogeny and heterogeneity of innate lymphoid cells and the noncoding genome
Michieletto, M. F., & Henao‐Mejia, J. (2021) · Immunological Reviews · doi:10.1111/imr.12950 · Cited by 11
Physiological and Aberrant γ-Globin Transcription During Development
Barbarani, G., Łabędź, A., Stucchi, S., Abbiati, A., & Ronchi, A. E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.640060 · Cited by 12
Yamaguchi, T., Yoshihiro, T., Ariyama, H., Ito, M., Nakano, M., Semba, Y., Nogami, J., Tsuchihashi, K., Yamauchi, T., Ueno, S., et al. (2022) · Gastric Cancer · doi:10.1007/s10120-022-01307-8 · Cited by 11
Self-citationDeWitt, M. A., Magis, W., Bray, N., Wang, T., Berman, J. R., Urbinati, F., Muñoz, D. P., Kohn, D. B., Walters, M. C., Carroll, D., et al. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/036236 · Cited by 12
Umhoefer, J. M., Arce, M. M., Kasinathan, S., Whalen, S., Dajani, R., Subramanya, S., Goudy, L., Belk, J. A., Zhou, R. W., Pham, M. T. N., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.10.020 · Cited by 16
Exa-cel in Children with Transfusion-Dependent β-Thalassemia or Sickle Cell Disease
Frangoul, H., de la Fuente, J., Chopra, Y. R., Meisel, R., Amrolia, P. J., Algeri, M., Sharma, A., Cappellini, M. D., Corbacioglu, S., Kattamis, A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2603387 · Cited by 11
Lau, C., & Suh, Y. (2017) · Mammalian Genome · doi:10.1007/s00335-017-9727-2 · Cited by 10
Cis-Regulatory Elements in Mammals
Liu, X., Chen, M., Qu, X., Liu, W., Dou, Y., Liu, Q., Shi, D., Jiang, M., & Li, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010343 · Cited by 12
Engineering Globin Gene Expression
Davis, R., Gurumurthy, A., Hossain, M. A., Gunn, E. M., & Bungert, J. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.004 · Cited by 10
Genomic annotation of disease-associated variants reveals shared functional contexts
Kyono, Y., Kitzman, J. O., & Parker, S. C. J. (2019) · Diabetologia · doi:10.1007/s00125-019-4823-3 · Cited by 9
Breaking enhancers to gain insights into developmental defects
Armendariz, D. A., Sundarrajan, A., & Hon, G. C. (2023) · eLife · doi:10.7554/elife.88187 · Cited by 9
Bloh, K. M., Bialk, P. A., Gopalakrishnapillai, A., Kolb, E. A., & Kmiec, E. B. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.04.009 · Cited by 10
From Reductionism to Holism: Toward a More Complete View of Development Through Genome Engineering
Delker, R. K., & Mann, R. S. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_3 · Cited by 10
Ctrl-Alt-inDel: genome editing to reprogram a cell in the clinic
Urnov, F. D. (2018) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2018.05.005 · Cited by 11
Modelling human haemoglobin switching
Diepstraten, S. T., & Hart, A. H. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.06.001 · Cited by 13
Druggable Transcriptional Networks in the Human Neurogenic Epigenome
Higgins, G. A., Williams, A. M., Ade, A. S., Alam, H. B., & Athey, B. D. (2019) · Pharmacological Reviews · doi:10.1124/pr.119.017681 · Cited by 10
Sensitive and reliable evaluation of single-cut sgRNAs to restore dystrophin by a GFP-reporter assay
Lyu, P., Yoo, K. W., Yadav, M., Atala, A., Aartsma-Rus, A. M., van Putten, M., Duan, D., & Lu, B. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239468 · Cited by 10
Liu, X., Yang, Y., Qiu, Y., Reyad‐ul‐Ferdous, M., Ding, Q., & Wang, Y. (2020) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2020.10.007 · Cited by 10
Gene Editing-Based Technologies for Beta-hemoglobinopathies Treatment
Rahimmanesh, I., Boshtam, M., Kouhpayeh, S., Khanahmad, H., Dabiri, A., Ahangarzadeh, S., Esmaeili, Y., Bidram, E., Vaseghi, G., Javanmard, S. H., et al. (2022) · Biology · doi:10.3390/biology11060862 · Cited by 11
Innovative Therapies for Hemoglobin Disorders
Sii-Felice, K., Nègre, O., Brendel, C., Tubsuwan, A., Morel-à-l’Huissier, E., Filardo, C., & Payen, E. (2020) · BioDrugs · doi:10.1007/s40259-020-00439-6 · Cited by 10
Genome Editing for Sickle Cell Disease: A Little BCL11A Goes a Long Way
Hossain, M. A., & Bungert, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.003 · Cited by 10
Genome editing for human osteoarthritis – a perspective
Almarza, D., Cucchiarini, M., & Loughlin, J. A. (2017) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2017.05.003 · Cited by 10
Functional genomic assays to annotate enhancer–promoter interactions genome wide
Leung, A. K.-Y., Li, Y., & Yu, H. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac204 · Cited by 9
From Genotype to Phenotype: How Enhancers Control Gene Expression and Cell Identity in Hematopoiesis
Mulet‐Lazaro, R., & Delwel, R. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000969 · Cited by 11
Quantifying allele-specific CRISPR editing activity with CRISPECTOR2.0
Assa, G., Kalter, N., Rosenberg, M., Beck, A., Markovich, O., Gontmakher, T., Hendel, A., & Yakhini, Z. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae651 · Cited by 9
Middlezong, W., Stinnett, V., Phan, M., Phan, B., Morsberger, L. A., Klausner, M., Ghabrial, J., DeMetrick, N., Zhu, J., James, T., et al. (2024) · Biomolecules · doi:10.3390/biom14121595 · Cited by 9
Treating genetic blood disorders in the era of CRISPR-mediated genome editing
Almotiri, A., Abogosh, A., Abdelfattah, A., Alowaisy, D., & Rodrigues, N. P. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.01.031 · Cited by 11
Caragine, C. M., Le, V. T., Mustafa, M., Diaz, B. J., Morris, J. A., Müller, S., Méndez‐Mancilla, A., Geller, E. T., Liscovitch‐Brauer, N., & Sanjana, N. E. (2025) · Nature Communications · doi:10.1038/s41467-025-56568-5 · Cited by 9
Self-citationButt, H., Mandava, M., & Jacobsohn, D. A. (2025) · The CRISPR Journal · doi:10.1089/crispr.2024.0101 · Cited by 9
Dorans, E., Jagadeesh, K. A., Dey, K. K., & Price, A. L. (2025) · Nature Genetics · doi:10.1038/s41588-025-02220-3 · Cited by 12
Roh, H., Shen, S. P., Yan, H., Kwok, H. S., Siegenfeld, A. P., Lee, C., Zepeda, M. L., Guo, C., Roseman, S. A., Comenho, C., et al. (2025) · Nature Methods · doi:10.1038/s41592-025-02811-2 · Cited by 12
Retroviral Vector Technology for Gene Therapy: History, Current Landscape, and Future Prospects
Jaballah, S. A., Ali, L. M., Jehad, M. A., Akhlaq, S., Rizvi, T. A., & Mustafa, F. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169473 · Cited by 10
Genome editing for sickle cell disease: still time to correct?
Ceglie, G., Lecis, M., Canciani, G., Algeri, M., & Frati, G. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1249275 · Cited by 14
Sickle cell disease in the era of precision medicine: looking to the future
Steinberg, M. H., Kumar, S. S., Murphy, G. J., & Vanuytsel, K. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1688658 · Cited by 9
β-Hemoglobinopathies: The Test Bench for Genome Editing-Based Therapeutic Strategies
Barbarani, G., Łabędź, A., & Ronchi, A. E. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.571239 · Cited by 8
CRISPR-Cas9 based genome editing for defective gene correction in humans and other mammals
Karapurkar, J. K., Antao, A. M., Kim, K.-S., & Ramakrishna, S. (2021) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2021.01.018 · Cited by 11
A synthetic synthesis to explore animal evolution and development
Perkins, M. L., Gándara, L., & Crocker, J. (2022) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2020.0517 · Cited by 9
Multiplexed functional genomic assays to decipher the noncoding genome
Cooper, Y. A., Guo, Q., & Geschwind, D. H. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac194 · Cited by 10
Omics Studies in Hemoglobinopathies
Katsantoni, E. Z. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00386-1 · Cited by 9
Multi-center integrated analysis of non-coding CRISPR screensPreprint
Yao, D., Tycko, J., Oh, J. W., Bounds, L. R., Gosai, S. J., Lataniotis, L., Mackay-Smith, A., Doughty, B. R., Gabdank, I., Schmidt, H., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.12.21.520137 · Cited by 9
Human genetics implicates a BACH2-NRF2 axis in fetal heamoglobin activationPreprint
Guo, C., Arora, U. P., Cheng, X., Xu, W., Cato, L. D., Li, R., Lu, H. Y., Lee, A., Yu, F., Agarwal, G., et al. (2023) · medRxiv · doi:10.1101/2023.03.24.23287659 · Cited by 9
Towards functional maps of non-coding variants in cancer
Wang, Y., & Hon, G. C. (2024) · Frontiers in Genome Editing · doi:10.3389/fgeed.2024.1481443 · Cited by 8
Paranthaman, S., Uthaiah, C. A., Md, S., & Alkreathy, H. M. (2025) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2025.103497 · Cited by 8
Cosenza, L. C., Zuccato, C., Zurlo, M., Gambari, R., & Finotti, A. (2022) · Genes · doi:10.3390/genes13101727 · Cited by 8
Forced enhancer-promoter rewiring to alter gene expression in animal models
Peslak, S. A., Demirci, S., Chandra, V., Ryu, B. Y., Bhardwaj, S. K., Jiang, J., Rupon, J. W., Throm, R. E., Uchida, N., Leonard, A. K., et al. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.01.016 · Cited by 9
Prasad, K. M., Devaraju, N., George, A., Ravi, N. S., Paul, J., Mahalingam, G., Rajendiran, V., Panigrahi, L., Venkatesan, V., Lakhotiya, K., et al. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102205 · Cited by 10
Self-citationThe therapeutic potential of genome editing for β-thalassemia
Glaser, A., McColl, B., & Vadolas, J. (2015) · F1000Research · doi:10.12688/f1000research.7087.1 · Cited by 8
Emerging cellular and gene therapies for congenital anemias
Ludwig, L. S., Khajuria, R. K., & Sankaran, V. G. (2016) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31529 · Cited by 9
Qiu, Y., Liu, X., Sun, Y., Li, S., Wei, Y., Tian, C., & Ding, Q. (2021) · Phenomics · doi:10.1007/s43657-020-00006-7 · Cited by 8
Angon, P. B., & Habiba, U. (2022) · Current Applied Science and Technology · doi:10.55003/cast.2022.03.23.003 · Cited by 9
Golov, A. K., Gavrilov, A. A., Kaplan, N., & Razin, S. V. (2024) · eLife · doi:10.7554/elife.91596.3 · Cited by 10
Proteomics and Precision Medicine
Ding, C., Qin, Z., Li, Y., Shi, W., Li, L., Zhan, D., & Yang, W. (2019) · Small Methods · doi:10.1002/smtd.201900075 · Cited by 9
DGK and DZHK position paper on genome editing: basic science applications and future perspective
Brandes, R. P., Dueck, A., Engelhardt, S. H., Kaulich, M., Kupatt, C., Angelis, M. T. D., Leisegang, M. S., le Noble, F. A. C., Moretti, A., Müller, O. J., et al. (2021) · Basic Research in Cardiology · doi:10.1007/s00395-020-00839-3 · Cited by 8
Robust regulatory interplay of enhancers, facilitators, and promoters in a native chromatin context
Zhou, Z., Cheng, Y., Lieberth, J., Zhang, J., Jin, Y., Li, A., Yu, H., Ozer, A., & Lis, J. T. (2026) · Cell · doi:10.1016/j.cell.2026.06.033 · Cited by 11
Huang, M., Ewadi, A., Servatian, N., Noormohamadi, H., Aminov, Z., Muzammil, K., Esfahani, M. A., Abak, N., & Samarkhazan, H. S. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104916 · Cited by 8
The Future of CRISPR Applications in the Lab, the Clinic and Society
Hough, S. H., & Ajetunmobi, A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-63904-8_9 · Cited by 7
CRISPR-mediated gene editing for the surgeon scientist
O’Brien, S. J., Ekman, M. B., Manek, S. E., & Galandiuk, S. (2019) · Surgery · doi:10.1016/j.surg.2019.01.030 · Cited by 7
Translating non-coding genetic associations into a better understanding of immune-mediated disease
Stankey, C. T., & Lee, J. C. (2023) · Disease Models & Mechanisms · doi:10.1242/dmm.049790 · Cited by 9
Efficient repair of human genetic defect by CRISPR/Cas9-mediated interlocus gene conversion
Yang, F., Wang, Y., Wang, Q., Pang, J., Liu, G., Yang, Y., Qin, S., Zhang, Y., Lai, Y., Fu, B., et al. (2023) · Life Medicine · doi:10.1093/lifemedi/lnad042 · Cited by 8
Self-citation
Metadata
- Authors
- Canver, M. C., Smith, E. C., Sher, F., Pinello, L., Sanjana, N. E., Shalem, O., Chen, D. D., Schupp, P. G., Vinjamur, D. S., Garcia, S. P., Luc, S., Kurita, R., Nakamura, Y., Fujiwara, Y., Maeda, T., Yuan, G.-C., Zhang, F., Orkin, S. H., & Bauer, D. E.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Broad Institute (US)
- RIKEN BioResource Research Center (JP)
- University of Tsukuba (JP)
- Brigham and Women's Hospital (US)
- Corresponding author
- Zhang, Feng
- Orkin, Stuart H.
- Bauer, Daniel E.
- ORCID
- Venue
- Nature
- Published
- 2015-09-16
- Volume
- 527
- Issue
- 7577
- Pages
- 192-197
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4644101
- OpenAlex
- W1855348513
- Cited by
- 886
- References
- 65
- Citations by year
- 2026: 43 · 2025: 72 · 2024: 76 · 2023: 79 · 2022: 68 · 2021: 91 · 2020: 85 · 2019: 92 · 2018: 87 · 2017: 94 · 2016: 89 · 2015: 8
- FWCI
- 51.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion)
- PMC
- Funders
- Howard Hughes Medical Institute
- U.S. Public Health Service (R01 A1084905)
- National Heart, Lung, and Blood Institute (P01HL032262, R01HL032259, R01HL119099)
- National Institute of Mental Health (DP1MH100706, R01MH110049)
- National Human Genome Research Institute (K99HG008171, R01HG005085, K99HG008399)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK049216, 5R01-DK097768, R01DK097768, F30DK103359, K08DK093705)
- National Center for Chronic Disease Prevention and Health Promotion (5DP1-MH100706)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- BCL11A, enhancers, CRISPR/Cas9, fetal hemoglobin, sickle cell disease, beta-thalassemia, enhancer architecture, erythroblasts
- MeSH terms
- RNA, Guide, CRISPR-Cas Systems, Animals, Base Sequence, Carrier Proteins, Cells, Cultured, DNA-Binding Proteins, Enhancer Elements, Genetic, Erythroblasts, Fetal Hemoglobin, Genetic Engineering, Humans, Molecular Sequence Data, Nuclear Proteins, Organ Specificity, Repressor Proteins, Species Specificity, Reproducibility of Results, Mutagenesis, Genome, Mice, Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR-Cas Systems, CRISPR-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
